Disclosed herein are compositions for use in and methods of producing HDAC11-activated macrophages. Also disclosed herein are methods of treating inflammation and providing adaptive cell therapy comprising HDAC11-activated M2 macrophages.

In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45.sup.+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.

A medium combination and a method for inducing iPSC differentiation to obtain macrophages and use thereof are provided. The medium combination includes a first stage medium to a sixth stage medium. The first stage medium is an E8 complete medium containing a ROCK pathway inhibitor and polyvinyl alcohol, the second stage medium is an E8 complete medium containing a GSK-3 inhibitor, the third stage medium includes an M1 medium and an M2 medium, the fourth stage medium is an M3 medium, the fifth stage medium is an M4 medium, and the sixth stage medium is an M5 medium.

Methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.

A medium combination and a method for inducing iPSC differentiation to obtain macrophages and use thereof are provided. The medium combination includes a first stage medium to a sixth stage medium. The first stage medium is an E8 complete medium containing a ROCK pathway inhibitor and polyvinyl alcohol, the second stage medium is an E8 complete medium containing a GSK-3 inhibitor, the third stage medium includes an M1 medium and an M2 medium, the fourth stage medium is an M3 medium, the fifth stage medium is an M4 medium, and the sixth stage medium is an M5 medium.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

The present invention provides a method for producing recombinant growth factors using an algal expression system, which offers advantages over traditional platforms, and the algae-derived growth factors can be used to formulate cell culture media for mammalian cells without the risk of pathogen contamination or endotoxins.

The subject invention pertains to a novel method for treating Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential of type 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This present invention aims at enhancing the muscle regeneration and revascularization for obese and diabetes individuals.

The present invention relates to a macrophage, genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). Such a macrophage may be for use in treatment of an inflammatory condition in a subject such as inflammatory organ damage. The inflammatory condition may be acute or chronic and may involve a fibrotic element.